They were sitting around a.

Catamaran bio series a. Catamaran Bio Inc a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer today announced that the company has launched with 42 million in financingSofinnova. Vipin Suri PhD MBA Chief Scientific Officer who has more than 20 years of biopharmaceutical experience including as a co-founder of Obsidian Therapeutics and Serien formerly Raze Therapeutics and earlier in R. This funding round was led by Lightstone Ventures and Sofinnova Partners and included participation from the founding investor of Catamaran Bio SV health investors.

This round is a part of their launch financing. November 23 2020 Catamaran Bio a Cambridge Mass-based developer of developing allogeneic CAR-NK cell therapies to treat cancer raised 42 million in Series A fundingSofinnova Partners and Lightstone Ventures co-led and were joined by Takeda Ventures Astellas Venture Management and founding backer SV Health Investors. Catamaran Bios founding members decided to jump into the CAR-NK game last December over drinks at a trendy bar in Boston.

Preclinical studies confirm that the biological features we are engineering into our CAR-NK cell therapies result in profound effects against solid tumors as well as hematologic malignancies. Sofinnova Partners Sofinnova Partners is a venture capital firm that invests in the life. Catamaran Bio is a biotechnology company that specializes in allogeneic immune cell therapies.

Seeded by SV Health Investors Catamaran launches with 42 million in combined seed and series A financing to develop off-the-shelf treatments based. About Catamaran Bio Catamaran Bio is developing novel off-the-shelf CAR-NK cell therapies designed to treat a broad range of cancers including solid tumors. The Daily Deal Newsletter Sign.

Catamaran Bio founded by life sciences investors and academic research groups including the UMN Technology Commercializations Venture Center has raised a whopping 42 million total through its seed and Series A funding rounds providing crucial support for the company to retain top talent and accelerate the development of its cancer therapies. Our internal Catamaran team combines its deep expertise in cell therapy with a passion. Catamaran Bio a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer has launched with 42 million in financing.

Catamaran Bio General Information Description. Other programs in our pipeline include potency-boosted CAR-NK cell therapies to address solid tumors that express novel surface markers. Catamaran Bio Inc a Cambridge Mass.